|Articles|September 9, 2014

Drugmaker Trains “Diabetes Ambassadors” in Africa

German drugmaker Merck KGaA has begun the second year of its five-year project to provide diabetes management courses for medical and pharmacy students in African Universities.

German drugmaker Merck KGaA has begun the second year of its five-year project to provide diabetes management courses for medical and pharmacy students in African Universities.

The Merck Capacity Advancement Program (CAP) will be provided at the Universities of Nairobi, Makerere, Uganda, and Namibia, before moving to Tanzania and Ghana. Merck is also offering every healthcare provider in those countries and the rest of Africa free access to the lectures via e-learning at www.managediabetesonline.org.

This year the company aims to reach 2,000 students and rural healthcare providers, who will have the opportunity to become “diabetes ambassadors” across Africa.

Merck’s Dr. Stefan Oschmann and Professor Sidat Mohsin, dean of the medical school at Eduardo Mondelane University, Mozambique.

The challenges faced by African countries in tackling diabetes are well known:  services for the care of chronic diseases are poorly organized; public awareness about diabetes is limited, and well-structured education programs for patients and health professionals are unavailable.

According to the International Diabetes Federation, the number of people with diabetes in Africa could double by 2035. The proportion of deaths due to diabetes in people under 60 years in Africa is currently 76%, and 46% of people living with diabetes are still undiagnosed.

Next year Merck’s program will be extended to more universities across Africa such as Nigeria and Ethiopia, and to Asian countries such as Indonesia and India.


Related to this article

Pharmaceutical Executive Daily
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.